Novo Nordisk beat consensus estimates on both sales as well as profitability, although FX headwinds wiped out the entire growth. Sales came in at DKK26.9bn, with the local currency growth of 5% dented by 10ppts of the negative FX movement. NB All sales growth numbers in LC, unless specified otherwise. The diabetes business grew by 6% in LC, while some benefits of tender timing in Latin America drove 1% growth in the long-struggling biopharma business (vs -10% in Q4 17, -12% in Q3, -15% in Q2
03 May 2018
First read: FX carnage on solid operational performance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
First read: FX carnage on solid operational performance
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
03 May 2018 -
Author:
Kamla Singh -
Pages:
3
Novo Nordisk beat consensus estimates on both sales as well as profitability, although FX headwinds wiped out the entire growth. Sales came in at DKK26.9bn, with the local currency growth of 5% dented by 10ppts of the negative FX movement. NB All sales growth numbers in LC, unless specified otherwise. The diabetes business grew by 6% in LC, while some benefits of tender timing in Latin America drove 1% growth in the long-struggling biopharma business (vs -10% in Q4 17, -12% in Q3, -15% in Q2